Skip to content
AnalystLens

IDEXX Laboratories Quarterly Report for Q1 Ended Mar 31, 2025

Filing Date
Filed May 1, 2025
Period End
March 31, 2025
Security
IDXX
One revenue dollarkept$0.24
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-Q filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories, Inc. reported a solid first quarter for 2025, with total revenue growing 3.6% to $998.4 milliona compared to the prior year.

This growth was primarily driven by a 4.7% increase in organic revenue, demonstrating continued underlying business strength, particularly within the Companion Animal Group (CAG) segment. The company also maintained healthy profitability, with income from operations rising 5.9% to $316.5 millionb and a gross profit margin improvement to 62.4%. Significant stock repurchases were undertaken during the quarter, indicating a commitment to returning capital to shareholders, although this also contributed to a decrease in cash and cash equivalents.

While the company navigated some headwinds, including foreign currency fluctuations which negatively impacted revenue growth by 1.2%c, the overall financial performance appears robust. Management expects continued growth, supported by new business gains, customer retention, and strategic investments in product development. The company also successfully managed its debt levels, maintaining compliance with its leverage ratio covenants, and has sufficient liquidity to fund operations and growth initiatives for the foreseeable future.

Key Highlights

  1. Total revenue increased by 3.6% to $998.4 million, driven by a 4.7% organic revenue growth.
  2. Companion Animal Group (CAG) remains the primary revenue driver, with revenue up 3.4% to $919.8 million, supported by recurring diagnostics and veterinary software/services.
  3. Gross profit margin improved by 90 basis points to 62.4%, reflecting favorable business mix and price realization that offset inflationary pressures.
  4. Income from operations grew 5.9% to $316.5 million, showcasing effective cost management across operating segments.
  5. The company repurchased a significant amount of its common stock, totaling $400.9 million in the current quarter, indicating a strong focus on shareholder returns.
  6. Cash and cash equivalents decreased to $164.0 million from $288.3 million, primarily due to substantial stock buybacks and a reduction in borrowings under the credit facility in the prior year.
  7. The company remains compliant with its financial covenants, specifically the consolidated leverage ratio, with a ratio of 0.58x net debt to Adjusted EBITDA.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2025, IDEXX Laboratories kept $0.24.

  1. Revenue$998.4M100.0%
  2. Cost of revenue−$375.0M37.6%
  3. Gross profit$623.4M62.4%
  4. Operating costs−$306.8M30.7%
  5. Operating income$316.5M31.7%
  6. Interest, other & tax−$73.9M7.4%
  7. Net income$242.7M24.3%
Computed from 10-QQ1 FY2025filed May 1, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2025 against Q1 FY2024

Line itemQ1 FY2025Q1 FY2024Change
Revenue$998.43M$964.10M+3.6%
Cost of Revenue$375.05M$371.02M+1.1%
Gross Profit$623.38M$593.07M+5.1%
R&D Expenses$59.06M$52.63M+12.2%
Operating Expenses$306.85M$294.11M+4.3%
Operating Income$316.53M$298.96M+5.9%
Net Income$242.68M$235.58M+3.0%
EPS (Basic)$2.98$2.84+4.9%
EPS (Diluted)$2.96$2.81+5.3%
Shares Outstanding (Basic)81.32M83.10M−2.1%
Shares Outstanding (Diluted)81.92M83.96M−2.4%

Frequently Asked Questions

  1. How did IDEXX's revenue perform in the first quarter of 2025?

    IDEXX reported total revenue of $998.4 million for the three months ended March 31, 2025, a 3.6% increase compared to the same period in the prior year. Organic revenue growth, which excludes the impact of foreign currency exchange rates and acquisitions, was 4.7%, highlighting the underlying strength of the business.

  2. What was the profitability like for IDEXX in this quarter?

    The company demonstrated strong profitability. Gross profit increased by 5.1% to $623.4 million, with a gross profit margin of 62.4%, up from 61.5% in the prior year. Income from operations increased by 5.9% to $316.5 million. Net income was $242.7 million, resulting in diluted earnings per share of $2.96.

  3. How is the company managing its cash and debt?

    IDEXX's cash and cash equivalents decreased to $164.0 million from $288.3 million at the end of the prior year, largely due to significant share repurchases. The company has $928.6 million in remaining borrowing availability under its $1.25 billion Credit Facility and has maintained compliance with its consolidated leverage ratio covenant (0.58x net debt to Adjusted EBITDA), indicating sound financial management.

  4. What are the key drivers of revenue growth?

    Revenue growth was primarily driven by the Companion Animal Group (CAG) segment, particularly from CAG Diagnostics recurring revenue, including IDEXX VetLab consumables, and veterinary software, services, and diagnostic imaging systems. The Water segment also contributed with higher realized prices and increased volumes. The company cited higher realized prices and increased volumes as key drivers across its segments.